Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir and Simeprevir with or without Ribavirin for HCV Genotype 1
NCT01628692Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2012
- Primary completion
- Aug 2013
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of daclatasvir, simeprevir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Jul 2012; status: completed.
02
Drugs
daclatasvirsimeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01628692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01628692.